The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company
With a wave of groundbreaking products in the pipeline, biotechnology could be poised to keep churning higher for the foreseeable future. But how can you get in on the ground floor of the next big wave in biotech?
See For Yourself
This New Technology Could Be A Game Changer For Global Security
One company has a technology product that could disrupt this multi-billion-dollar industry for the better. And not just all of the countless lives saved – but investors too could benefit. How? To first understand this, you need to grasp the sheer scope of this market.
Continue Reading
GT Biopharma (GTBP) Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics
TAMPA, Florida, Sept. 24, 2019 /PRNewswire/ — GT Biopharma, Inc. (GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company’s proprietary NK cell engager (TriKE™) platform and Multi-Target Directed Bispecific Drug Conjugate platform, announced today that it sold the rights to GTB-004 for the treatment of myasthenia gravis to DAS Therapeutics, Inc.
Read Full Release
